Bitcoin, Ether near record highs as Treasury play keeps growing
As of late afternoon in New York, Bitcoin traded above $122,000 on Wednesday, leaving it about 1% below its July peak. Ether, meanwhile, has shaken off a prolonged spell of underperformance, and is little more than a hundred dollars shy of its 2021 bull market record. The second-largest token has led a surge that pushed total crypto market capitalization to a record $4.2 trillion, according to data compiled by CoinGecko.
The rally in Ether has been fueled by record inflows into funds directly investing in the token and a growing number of so-called Ether-focused treasury firms — public companies modeled after Michael Saylor's Bitcoin accumulation strategy. These entities have collectively absorbed nearly $17 billion worth of Ether, according to data compiled by StrategicEthReserve.xyz.
180 Life Sciences Corp., which conducts business under the name ETHZilla, has surged more than 200% this week. The biotechnology turned Ethereum treasury company, backed by billionaire Peter Thiel, announced Tuesday that it holds 82,186 Ether tokens.
In August, US spot Ether ETFs have attracted more than $1.7 billion in net inflows, while Bitcoin funds saw $436 million in outflows, according to data compiled by Bloomberg. On Tuesday, for the first time since their launch, the nine US spot Ether ETFs posted more trading activity than their dozen Bitcoin counterparts. Open interest in Ether futures across exchanges also climbed to a record $66 billion, Coinglass data show.
'The July passage of the US GENIUS Act, which clears the way for mainstream adoption of stablecoins, is a pivotal change,' Geoff Kendrick, global head of digital assets research at Standard Chartered wrote in a Wednesday report. 'Stablecoins account for 40% of all blockchain fees today, and more than 50% of stablecoins sit on Ethereum. The GENIUS Act should indirectly boost Ethereum's layer one activity as increased stablecoin liquidity leads to more decentralized finance (DeFi) activity, where ETH dominates.'
Standard Chartered now sees Ether hitting $7,500 by the end of 2025, up from a previous $4,000 target.
'Bitcoin's push toward a new all-time high is unfolding against a macro backdrop that's turned decisively supportive,' said Sui Chung, CEO of CF Benchmarks.
Shukla writes for Bloomberg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Tencent's Earnings Beat Sparks Price Targets Showing 16% Gain
(Bloomberg) — Chinese social media giant Tencent Holdings Ltd.'s ( TCEHY) strong earnings beat this week led more than two dozen analysts to lift their price targets for its stock, suggesting room for double-digit percentage gains over the next 12 months. Tencent's target price consensus has jumped by more than 5% to HK$688 since it reported quarterly results on Wednesday, according to Bloomberg calculations. That is the second biggest post-earnings jump in its price target over the past five years, beaten only by a March shift fueled by optimism around AI start-up DeepSeek. The US-Canadian Road Safety Gap Is Getting Wider Festivals and Parades Are Canceled Amid US Immigration Anxiety To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets The new consensus price suggests potential gains of almost 16% over the next 12 months, based on the stock's HK$594.50 price during Friday's trading session. At least 16 brokers are now forecasting the company's shares to rally above its historical high seen in 2021, erasing losses triggered by China's years-long crackdown on the private sector. They are bullish about the company's upcoming release of mobile game next Tuesday, seen as a key driver of its second-half gaming revenue. Tencent reported a 15% jump in revenue to 184.5 billion yuan ($25.7 billion) in the June quarter, beating analysts' projections. That was driven by double-digit growth in most major business segments including advertising, which it attributed to AI-driven enhancements. Americans Are Getting Priced Out of Homeownership at Record Rates What Declining Cardboard Box Sales Tell Us About the US Economy Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Dubai's Housing Boom Is Stoking Fears of Another Crash Twitter's Ex-CEO Is Moving Past His Elon Musk Drama and Starting an AI Company ©2025 Bloomberg L.P. Sign up for the Yahoo Finance Morning Brief By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Intel's Frankfurt-listed shares rise 3.6% after report US could take stake in chipmaker
LONDON (Reuters) -Intel's Frankfurt-listed shares rose 3.6% on Friday, a day after Bloomberg News reported the Trump administration is in talks with the struggling chipmaker to have the U.S. government potentially take a stake in the company. Intel's U.S. shares surged more than 7% in regular trading Thursday and then another 2.6% after the bell. Intel on Thursday declined to comment on the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Android Authority
11 minutes ago
- Android Authority
Blood pressures rise as the FDA cracks down on this wearable's flagship feature
WHOOP TL;DR The FDA has scrutinized Whoop for a new wellness monitoring feature that has not been certified. The FDA considers the Whoop MG (Medical Grade) a medical device and should remove the Blood Pressure Insights feature until approved. Whoop claims the product is not for medical use and will not disable the feature. Wellness wearable maker Whoop, specifically one of its latest fitness bands, has drawn the ire of the FDA after it debuted a feature not approved or certified by the authority. Per a Bloomberg filing, the FDA is pressuring Whoop to disable its Blood Pressure Insights feature. This new app offers its wearers blood pressure estimates and related guidance to provide a holistic view of their well-being. However, the FDA and Whoop can't seem to agree whether the MG's feature constitutes a medical device and must go through the traditional regulatory channels. WHOOP Whoop's marketing material claims that the MG is 'not a medical device and cannot diagnose or manage medical conditions,' and, as a result, the FDA has no authority to 'regulate the product.' However, the FDA seemingly believes otherwise, claiming that potentially erroneous blood pressure readings can harm those wearing the device. Regardless, Whoop reportedly has confirmed that it would not remove the feature, going against the recent trends of health tech firms relenting to the agency. Don't want to miss the best from Android Authority? Set us as a preferred source in Google Search to support us and make sure you never miss our latest exclusive reports, expert analysis, and much more. Medical devices must go through the relevant FDA channels for testing and approval before being marketed and sold; this includes unproven and novel sensors on smartwatches and fitness trackers. While the process ensures consumers are offered clinically-approved products, it can take months, often resulting in features launching well after a device has debuted. The Fitbit Sense's ECG sensor is a particularly memorable example of this. The FDA can demand fines from offending companies or even forbid their products from being sold. Still, the genuine issue appears to be the nebulous definitions of medical devices and modern fitness trackers. We've seen wellness wearable makers debut numerous features in recent years, but blood pressure readings and guidance remain relatively novel. The Samsung Galaxy Watch line and Garmin products like the Index include similar features, but both Korean and American companies have undergone the relevant approval processes before launch. Despite its firm stance, Whoop has reportedly requested an audience with the FDA to clarify the situation, but it's unclear how this tussle will ultimately affect Whoop MG owners. The screenless wellness band debuted for $359 alongside the Whoop 5.0 in May, but the Blood Pressure Insights feature is available only to premium subscribers. Follow
